Dr. Friedman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Mass General Cancer Center at Newton-Wellesley
Newton-Wellesley Hospital
Newton, MA 02462Phone+1 617-219-1230
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2002 - 2004
Georgetown University School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - Present
MA State Medical License 2004 - 2026
VA State Medical License 2002 - 2004
MD State Medical License 1998 - 2000- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Publications & Presentations
PubMed
- 140 citationsUmbilical Cord Mesenchymal Stem Cells: Adjuvants for Human Cell TransplantationRobb Friedman, Monica Betancur, Laurent Boissel, Hande H. Tuncer, Curtis L. Cetrulo
Biology of Blood and Marrow Transplantation. 2007-12-01 - 49 citationsAtorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.Tomas G Neilan, Thiago Quinaglia, Takeshi Onoue, Syed S Mahmood, Zsofia D Drobni
JAMA. 2023-08-08 - 27 citationsTargeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophiliaMonica Kasbekar, Valentina Nardi, Paola Dal Cin, Andrew M. Brunner, Meghan Burke
Blood Advances. 2020-07-14
Abstracts/Posters
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for ImmunotherapyRobb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple MyelomaRobb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaRobb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
